Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Capital cut Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Trading Up 2.4 %

Cyclacel Pharmaceuticals stock opened at $0.38 on Friday. The firm has a market cap of $2.39 million, a PE ratio of -0.04 and a beta of 0.35. The stock’s 50 day simple moving average is $0.37 and its two-hundred day simple moving average is $0.84. Cyclacel Pharmaceuticals has a 12 month low of $0.31 and a 12 month high of $4.00.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.